Faron Pharmaceuticals Oy, a clinical stage biopharmaceutical company, has announced amendments to its financial reporting calendar for 2023. The company's financial statement release for the full year 2023 and Annual Report 2023, including financial statements for the full year, will now be published on March 13, 2024, instead of the previously communicated date. The change in the financial calendar is attributed to the breach of the Funding Agreement between IPF and Faron, announced on February 19, 2024, which has impacted the Board's ability to approve the accounts for the full year 2023 for publication.

The publication date for Faron's half-year financial report for the period January 1 to June 30, 2024, remains unchanged, set for Tuesday, August 27, 2024. Additionally, the Annual General Meeting is planned to be convened on Friday, April 5, 2024, with a separate stock exchange notice to be issued by Faron's board of directors to convene the meeting.

Following the publication of the financial statement release for the full year 2023 on March 13, 2024, Dr. Markku Jalkanen, Chief Executive Officer, and James O'Brien, Chief Financial Officer, will host a virtual briefing and Q&A session for analysts. The full year results press release for 2023, presentation, virtual briefing webcast details, and Annual Report 2023 will be made available at www.faron.com/investors. A replay of the analyst briefing will also be provided shortly afterwards.

For more information about the analyst briefing, interested parties can contact [email protected]. Capitalized terms used in the announcement will have the same meanings as set out in the Company's announcement of February 19, 2024.

For further details, investors can contact the provided Investor Contact and the company's Nomad, Broker, and Certified Adviser on Nasdaq First North.